Imipramine (Janimine)

The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.

Also Known As:

Networked: 1713 relevant articles (161 outcomes, 264 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Tikhonova, M A: 7 articles (01/2015 - 08/2002)
2.	Kulikov, A V: 6 articles (01/2015 - 08/2002)
3.	Bruijn, Jan A: 6 articles (06/2010 - 08/2002)
4.	van den Broek, Walter W: 6 articles (06/2010 - 11/2002)
5.	Popova, N K: 5 articles (01/2015 - 08/2002)
6.	Dudek, Dominika: 5 articles (11/2007 - 11/2002)
7.	Mavissakalian, Matig R: 5 articles (03/2004 - 03/2002)
8.	Birkenhäger, Tom K: 4 articles (06/2010 - 10/2004)
9.	Wróbel, Andrzej: 4 articles (11/2007 - 11/2002)
10.	Rogóz, Zofia: 4 articles (11/2007 - 11/2002)

Related Diseases

1.	Panic Disorder (Panic Attack) 06/01/1998 - "Imipramine has proven efficacy for panic disorder. " 12/01/2001 - "Emotion-focused psychotherapy was less effective for symptoms of panic disorder than treatment with either cognitive behavior therapy or imipramine; results obtained with emotion-focused psychotherapy after the acute and maintenance phases were similar to those seen with placebo. " 08/01/2014 - "The results suggest that low-dose imipramine may be useful for the treatment of panic disorder during pregnancy. " 11/01/1987 - "Ten of the patients improved markedly on imipramine in an open drug trial design which lasted 3 months; the two non-responders had both situational and spontaneous panic attacks. " 02/01/2007 - "The authors assessed whether adding cognitive behavior therapy (CBT) to imipramine for patients with panic disorder decreased the severity of side effects and dropouts from side effects. "
2.	Depressive Disorder (Melancholia) 12/01/1975 - "Two of the three trials of imipramine in neurotic depression gave results showing significant improvement. " 07/01/1992 - "After six weeks of treatment the results showed that the scores on the Hamilton Depression Scale as well as on the Melancholia Scale were significantly more improved in the imipramine-plus-minaserin group than in the group of patients receiving imipramine alone (P less than 0.01). " 05/01/1999 - "Imipramine was more effective against the clusters related to core symptoms of depression: "depression and guilt", "retardation", and "melancholia", respectively. " 04/01/1994 - "The authors' first objective was to ascertain whether imipramine is superior to placebo in treating axis I depressive disorders in the context of HIV illness. " 04/01/1993 - "Alternatively, if cognitive therapy and imipramine are effective for different subtypes of depressive disorder, then imipramine ought to be more effective than placebo for patients failing to benefit from cognitive therapy because some potential imipramine failures would already have been removed. "
3.	Enuresis 06/01/2004 - "Imipramine is a useful treatment for enuresis when everything else has failed, especially among older children. " 08/10/1968 - "Efficacy of imipramine in childhood enuresis: a double-blind control study with placebo." 01/01/1994 - "Plasma levels and efficacy of imipramine treatment for enuresis." 10/01/1970 - "The efficacy of imipramine in the management of enuresis." 12/21/1968 - "Efficacy of imipramine in childhood enuresis."
4.	Major Depressive Disorder (Major Depressive Disorders) 03/01/2004 - "Both the prototypic tricyclic antidepressant imipramine (IMI) and the herbal product St John's wort (SJW) can be effective in the treatment of major depressive disorder. " 03/01/2000 - "To investigate the efficacy of 8 weeks of imipramine versus placebo in combination with cognitive-behavioral therapy (CBT) for the treatment of school-refusing adolescents with comorbid anxiety and major depressive disorders. " 01/01/1997 - "We carried out two dose finding placebo- and imipramine-controlled, double-blind, multicenter and multinational trials (northern part of Europe) with a new psychotropic compound (NPC) currently being investigated in Phase II/III as a potential antidepressant in the indication major depressive disorder (MDD). " 09/01/1990 - "A kinetic model for imipramine (IMI) has been developed, based upon a study of 16 teenagers who received IMI 4-5 mg/kg/day for treatment of a major depressive disorder. " 07/01/1989 - "Results of a randomized double-blind comparative trial versus imipramine involving 64 in-patients with Major Depressive Disorder (DSM III) in six independent centers will be presented and discussed. "
5.	Agoraphobia 08/01/1992 - "The results support the hypothesis that successful imipramine maintenance treatment of patients with panic and agoraphobia can have protective effects against relapse, at least in the first 6 months after the maintenance treatment period." 06/01/1988 - "This study was designed to see whether the high vs low serum level of imipramine influenced the outcome of in vivo exposure therapy on patients with agoraphobia. " 06/01/1987 - "The greater dose effect observed in the low depressed group and the greater response rates found among high-dose patients with low initial depression strongly suggest that the beneficial effect of imipramine in agoraphobia was not primarily antidepressant in nature." 06/01/1987 - "Initial depression and response to imipramine in agoraphobia." 05/01/1987 - "Imipramine treatment of agoraphobia."

Related Drugs and Biologics

1.	Alprazolam (Xanax)
2.	Amitriptyline (Elavil)
3.	Phenelzine (Nardil)
4.	Tricyclic Antidepressive Agents (Tricyclic Antidepressants)
5.	Desipramine (Pertofrane)
6.	Clomipramine (Anafranil)
7.	Fluvoxamine (Luvox)
8.	Paroxetine (Paxil)
9.	Antidepressive Agents (Antidepressants)
10.	Fluoxetine (Prozac)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Aftercare (After-Treatment)
3.	Hemoperfusion
4.	Phototherapy (Light Therapy)
5.	Transcutaneous Electric Nerve Stimulation (TENS)